Skip to content
Healthcare Capital Partners
  • Home
  • About
  • Transactions
  • Areas of Expertise
  • Management
  • Contact
The,Iconic,Skyline,Of,London,,United,Kingdom,,During,Sunset,Time
London
Panoramic,View,Of,Historic,Zurich,City,Center,With,Famous,Fraumunster,
Zurich
Skyline,Of,Downtown,Boston,From,The,Pier
Boston

Sales and Divestitures

Sales and Divestitures

  • Sale mandates
  • Recapitalisations
  • Shareholder restructurings
  • Business reviews

Mergers and Acquisitions

Mergers and Acquisitions

  • Acquisition mandates
  • Leveraged and management buyouts
  • Post deal strategy and implementation
  • Mergers mandates

Private Placements

Private Placements

  • Private equity
  • Private debt and mezzanine
  • Refinancing

Advisory Services

Advisory Services

  • Corporate development
  • Intellectual property management
  • Strategic and capital market alternatives
  • Acquisition

About

HCP is a healthcare and life sciences investment banking firm created to advise small and middle-market healthcare companies. Its partners have completed more than 100 transactions in the healthcare sector with a value in excess of $1 billion. The majority of transactions ranged in size from $10-100m. HCP advises healthcare and life sciences companies in identifying and structuring value-enhancing transactions primarily between the US and Europe. It focuses on business and assets divestitures, private equity and venture capital fund raising. HCP’s competitive advantages include:

  • a focused healthcare/life sciences seasoned professional trans-Atlantic team
  • leveraging our European and US investment bankers’ transaction experience
  • drawing upon our experience as senior members of European and US healthcare and life sciences companies to advise clients on corporate or project strategy
  • accepting equity participation in lieu of cash for advisory fees

HCP focuses on the life sciences, pharmaceutical, medtech, and healthcare services.

transactions

HCP advises small and middle-market healthcare companies. Its partners have completed more than 100 transactions in the healthcare sector with a value in excess of $1bn. HCP advises healthcare companies in identifying and structuring value-enhancing transactions primarily between the US and Europe. It focuses on business and assets divestures, private equity and venture capital fund raising.

Sebia - Secondary Buy- Out of French Diagnostics Company

Advisor to the Management team of French diagnostics manufacturer Sebia on the secondary buyout by Montagu Private Equity from Astorg Partners

sebia.com

Renal Services – Sale of the company

Advisor to the shareholders of UK dialysis company Renal Services on its sale to DaVita International

renalservices.com

CathNet Sciences SA – Sale of a Medtech company controlled by Boston Scientific

Advisers to Boston Scientific and management on the sale of ICV company CathNet Sciences SA

bostonscientific.com

Nagor - Sale of UK breast and Silicone Implant company Nagor

Advisor to private British Silicone implant manufacturer Nagor on sale to US public company Medicor Limited

nagor.com

Lantor UK - Sale of Wound Care Company

Advisor to private equity fund Horizon Partners Limited on the sale of Lantor UK to BFF Technical Fabrics

lantor.co.uk

Biosil - Sale of UK breast and Silicone Implant company Biosil

Advisor to private British Silicone implant manufacturer Biosil on sale to US public company Medicor Limited

biosil.com

Minvasys - Sale of French Cardiovascular Devices Manufacturer

Advisor to French private company Minvasys focusing on the design, development and manufacturing of cardiovascular stents on the sale of its core business to a strategic buyer

minvasys.com

Labnova – Sale of specialty chemical company

Advisor to the shareholders of a private Italian chemical reagents manufacturer to Japanese medtech company Nihon Kohden

nihonkohden.com

Arthesys - Sale of Non-Core Assets by French IVC Company

Advisor to private French Interventional Cardiology company Arthesys on disposal of Non-Core Assets

arthesys.com

Lipoxen – identified and structured pre-IPO investment

Advisor to a Russian investment group – identified and structured the investment in a UK biotech company prior to IPO

lipoxen.com

IGNA - Sale of France Largest Genetic Testing Laboratory

Advisor to private equity funds Rothschild and Matigonon on the sale of IGNA to a strategic buyer

igna.fr

OrthoRehab - Sale of US Orthopedic Products company OrthoRehab

Advisor to the shareholders of private US orthopedic company Ortho Rehab Inc. on sale to German company Otto Bock Healthcare LP

orthorehab.com

Medicom - Sale of Bang & Olufsen Drug Delivery Devices Subsidiary

Advisor to Bang & Olufsen on the sale of a non-core medical subsidiary to a private equity fund

medicomnordic.com

Stirling Square Capital Parnters - MBO of European Dialysis Provider

Advisor to private equity fund Stirling Square Capital Partners on the MBO of Baxter's Dialysis Services division

stirlingsquare.com

Cannaray – Private placement of equity and debt

Advisor to UK cannabis company Cannaray on private placements of equity and debt

cannaraycbd.com

Santersus – Private placement of equity and debt

Advisor to Swiss therapeutic company Santersus on private placements of equity and debt

santersus.com

Area of expertise

pexels-artem-podrez-5726794

Pharma

Pharma

pexels-rodnae-productions-6129242

Medtech

Medtech

pexels-anna-shvets-4225920

Life Sciences

Life Sciences

pexels-cdc-3993214

Patient Care

Patient Care

pexels-andrea-piacquadio-3952126

Digital Health

Medtech

Management

Cb6aGq9g-002
Stefano Ciampolini

Managing Partner

R--032
M. Scott Maguire
Partner
Klaus Bak
Klaus Bak
Associate Partner Scandinavia

Our competitive advantage lies in having senior HCP members and global industry experts as project leaders. Our senior team members maintain day-to-day involvement with the client and actively direct our analyst teams.

Our trans-Atlantic alliance allows us to customize project strategies by incorporating critical market, regulatory and other considerations into the project. In many cases after completing a transaction, our senior members maintain an active dialogue and participation with the client. This participation has included continuing advisory work for the existing business, identifying new opportunities for the client and participating as a shareholder in the client’s business.

Unlike other investment banking firms, we, in many instances, take equity stakes in our clients’ companies instead of cash payments for our fees. As a shareholder and/or board member, we continue to provide expert financial and strategic advice to the client company.

Contact info

Healthcare Capital Partners Limited

  • 17 Ives Street
    London SW3 2ND
    United Kingdom
  • E-mail: [email protected]

Contact form

    © 2026 Healthcare Capital Partners